Iovance Biotherapeutics Inc: Baird assumes coverage with neutral rating; target price $6
IOVA•Related News
Spyre Therapeutics Inc <SYRE.O>: Baird assumes coverage with outperform rating; target price $120
SYRE•
HIVE unit BUZZ HPC signs five-year GPU cloud services deal worth USD 350 million
HIVE•
JLL: Jefferies raises target price to $437 from $383
JLL•
Genco Shipping says Diana Shipping withdraws bid for remaining shares
GNK•
GRAINS-Wheat extends rally as Black Sea risks, US dryness support prices
DBA•